nmsg

Cellectis and Accelera (Nerviano Medical Sciences Group) sign an agreement to complete preclinical studies of Cellectis lead product candidate UCART19

June 5, 2014 – Milan (Italy) and Paris (France) – Cellectis (Alternext: ALCLS.PA), a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis’ advanced product candidate, UCART19. Engineered allogeneic CD19 T-cells currently stand out as a real therapeutic innovation for treating B-cell leukemias and lymphomas.

Under the terms of this agreement, Accelera, a leading European CRO, will perform in vivo preclinical studies to finalize the IND (Investigational New Drug) / IMPD (Investigational Medicinal Product Dossier) package for UCART19. The Phase I human clinical trial for UCART19 is planned for 2015.

Dr Mathieu Simon, MD, Executive Vice-President at Cellectis stated: “Thanks to the extremely positive in vivo proof of concept results for our flagship UCART19 product, we are delighted to take a step forward with Accelera in order to complete the regulatory documents necessary for filing the IMPD package.”

Enrico Pesenti, Managing Director at Accelera said: “The collaboration with Cellectis confirms Accelera exclusive competence in designing and executing preclinical programs with innovative biologicals and cell based therapies. The agreement is also a significant sign of confidence in the outstanding quality of the scientific and industrial research Nerviano Medical Sciences Group develops today.”

About Cellectis
Cellectis is a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-ofthe-art electroporation technology Pulse Agile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Cellectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology.
CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Cellectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.
 
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.
 
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.